Cardiac safety plays a critical role in enabling confident, timely decisions in early-phase trials.
At Biokinetica, we combine state of the art faciilities with complex Phase 1 capabilities, precise QTc analysis, and real-time oversight to deliver reliable, high-quality cardiac data. From centralized ECG monitoring to automated detection of early safety signals, we support faster, data-driven decisions.
At the same time, our patient-centric approach — including wireless, low-burden systems and continuous monitoring — enhances both participant experience and data quality.
👇 Explore the document below to see how our integrated cardiac safety capabilities support faster insights, stronger data, and confident decision-making from first-in-human studies onward.
